Rheumatology

Your Article Summary

See Latest Articles

Anticytokine therapy in non-rheumatoid arthritis indications in 2009
Current Opinion in Rheumatology, 05/01/09

Villa-Forte A et al. – TNF-α inhibitors have been a major advancement in the treatment of a number of inflammatory joint diseases and are widely available in clinical practice; future research will need to continuously assess its longitudinal efficacy and safety.

• A review of the current uses of TNF-α therapies for non-rheumatoid arthritis inflammatory joint diseases
• Emphasis is given to important questions regarding their long-term use

• TNF-α blockade is one of the anticytokine therapies with major impact in the treatment of:
  • Rheumatoid arthritis (RA)
  • Ankylosing spondylitis
  • Psoriatic arthritis, and
  • Juvenile idiopathic arthritis (JIA)
    among the inflammatory joint diseases
• As a result of the impressive response to TNF-α inhibitors, new agents continue to be developed and a few are currently being tested in phase III trials
• Evaluation of a relationship between inflammation and structural damage in ankylosing spondylitis has been an important focus of recent studies
• Other aspects of treatment is long-term safety and selection of pts who will likely have a major response

Today in Other Arthritis...keeping you current

Receive free subspecialty "5-minute updates" via email

Hepatoprotective effect of TNF-alpha blockade in psoriatic arthritis: A cross-sectional study
Annals of Rheumatic Diseases, 11/09/09

The use of complementary and alternative medicine in outpatients with inflammatory rheumatic diseases in Sweden
Scandinavian Journal of Rheumatology , 11/17/09

Update in treatment options for psoriatic arthritis
Expert Review of Clinical Immunology, 11/23/09

See All of Other Arthritis